↓ Skip to main content

Dove Medical Press

Article Metrics

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

Overview of attention for article published in Biologics: Targets & Therapy, September 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
17 Mendeley
Title
Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
Published in
Biologics: Targets & Therapy, September 2015
DOI 10.2147/btt.s60503
Pubmed ID
Authors

Marco Montillo, Alessandra Tedeschi, Roberto Cairoli, Anna Maria Frustaci, Paola Picardi

Abstract

Treatment aim for chronic lymphocytic leukemia has been radically changed over the past years from providing only a palliative approach to reaching disease eradication and improving survival. Ofatumumab is a monoclonal humanized antibody with peculiar in vitro and in vivo properties, at present approved for double fludarabine and alemtuzumab refractory chronic lymphocytic leukemia. Its efficacy in this subset of patients, who typically have an unfavorable prognosis, facilitated its use in different Phase II and III trials. Ofatumumab as single agent or combined with chemotherapeutic or biologic agents, led to sundry results in the setting of both previously treated or untreated patients. Its role in maintenance therapy is also under investigation. Further advances concerning ofatumumab administration as first line therapy in combination with chlorambucil, came recently from the COMPLEMENT 1 study. Results from this trial will open the door to new perspectives of its use in treatment-naïve patients. Ofatumumab was well tolerated in almost all the studies, with the main adverse events relating mostly to infusion reaction. Hematologic toxicity, especially neutropenia, was also common. A significant improvement in patients' quality of life was reported following ofatumumab treatment and this was mainly due to its effect on constitutional symptoms. Nevertheless, some concerns remain regarding the long-term efficacy of the drug in terms of response duration and survival. The real strength of this drug needs to be confirmed by further studies and direct comparative trials.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 24%
Other 3 18%
Student > Ph. D. Student 3 18%
Student > Bachelor 2 12%
Unspecified 2 12%
Other 3 18%
Readers by discipline Count As %
Medicine and Dentistry 6 35%
Agricultural and Biological Sciences 3 18%
Unspecified 2 12%
Pharmacology, Toxicology and Pharmaceutical Science 1 6%
Sports and Recreations 1 6%
Other 3 18%
Unknown 1 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2015.
All research outputs
#20,292,660
of 22,829,083 outputs
Outputs from Biologics: Targets & Therapy
#234
of 273 outputs
Outputs of similar age
#229,053
of 272,855 outputs
Outputs of similar age from Biologics: Targets & Therapy
#4
of 4 outputs
Altmetric has tracked 22,829,083 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 273 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,855 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.